文献速递类风湿关节炎

Filgotinib单药治疗活动性类风湿关节炎的剂量探索研究(DARWIN 2)

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
PubMed 文献 · Ann Rheum Dis · 2016-12-19

DARWIN 2是一项24周IIb期随机对照研究,283例MTX应答不佳的活动性RA患者随机接受Filgotinib 50/100/200 mg每日一次或安慰剂单药治疗。第12周各剂量组ACR20应答率≥65%,显著高于安慰剂组的29%(p<0.001),100和200 mg组在其他关键终点亦显著优于安慰剂,疗效维持至24周,总体耐受性良好。

要点

  • Filgotinib单药治疗MTX应答不佳的活动性RA,第12周ACR20应答率≥65%,安慰剂组29%(p<0.001)。
  • 100和200 mg组在ACR50、ACR70、DAS28-CRP、CDAI、SDAI、HAQ-DI等终点显著优于安慰剂,疗效维持至24周。
  • 不良事件发生率与安慰剂组相似(约40%),未报告结核或机会性感染。

核心结论

  • Filgotinib单药治疗活动性RA在24周内有效,起效迅速,总体耐受性良好。

研究设计与样本

  • 24周IIb期随机、安慰剂对照、剂量探索研究,283例中重度活动性RA且MTX应答不佳的患者随机(1:1:1:1)接受Filgotinib 50、100或200 mg每日一次或安慰剂,MTX洗脱≥4周。

主要发现

  • 第12周任一剂量Filgotinib组达到ACR20应答的患者比例显著高于安慰剂组(≥65% vs 29%,p<0.001)。
  • 第12周100和200 mg组在ACR50、ACR70、ACR-N、DAS28-CRP、CDAI、SDAI和HAQ-DI等关键终点显著优于安慰剂,应答维持或改善至第24周。
  • 多数疗效终点观察到快速起效,血红蛋白呈剂量依赖性升高。
  • 安慰剂组与Filgotinib组治疗中出现不良事件(TEAE)的患者比例相似(约40%)。
  • Filgotinib组8例、安慰剂组1例发生严重TEAE;4例严重感染均发生在Filgotinib组,未报告结核或机会性感染。

关键数值与推荐

  • 主要终点为第12周ACR20应答率,Filgotinib任一剂量组≥65%,安慰剂组29%(p<0.001)。

临床怎么用

  • 对于MTX应答不佳的活动性RA患者,Filgotinib单药可考虑作为治疗选择,100和200 mg剂量在多项疗效终点上显著优于安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX). METHODS: In this 24-week phase IIb study, patients with moderately to severely active RA were randomised (1:1:1:1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a ≥4-week washout from MTX. The primary end point was the percentage of patients achieving an American College of Rheumatology (ACR)20 response at week 12. RESULTS: Overall, 283 patients were randomised and treated. At week 12, significantly more patients receiving filgotinib at any dose achieved ACR20 responses versus placebo (≥65% vs 29%, p<0.001). For other key end points at week 12 (ACR50, ACR70, ACR-N, Disease Activity Score based on 28 joints and C reactive protein, Clinical Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index) significant differences from baseline in favour of filgotinib 100 and 200 mg versus placebo were seen; responses were maintained or improved through week 24. Rapid onset of action was observed for most efficacy end points. Dose-dependent increases in haemoglobin were observed. The percentage of patients with treatment-emergent adverse events (TEAE) was similar in the placebo and filgotinib groups (∼40%). Eight patients on filgotinib and one on placebo had a serious TEAE, and four patients, all of whom received filgotinib, experienced a serious infection. No tuberculosis or opportunistic infections were reported. CONCLUSIONS: Over 24 weeks, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action. Filgotinib was generally well tolerated. TRIAL REGISTRATION NUMBER: NCT01894516.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2016. PMID: 27993828. doi:10.1136/annrheumdis-2016-210105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。